Kodikaz is a gene therapy platform that employs targeted delivery systems to selectively destroy cancer cells while preserving healthy tissue. This technology provides a more effective treatment option for patients by reducing the adverse effects commonly associated with traditional cancer therapies.
Funding
$3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
NSFounders
Product
Problem
Traditional cancer therapies often lack specificity, leading to the destruction of healthy cells alongside cancerous ones. This non-selective targeting results in significant adverse effects, limiting the effectiveness and tolerability of treatment, especially for patients with advanced or aggressive cancers.
Solution
Kodikaz is developing a gene therapy platform based on its Zip-Code™ Technology, a cell-specific delivery system designed to selectively target and destroy cancer cells while sparing healthy tissue. The platform utilizes an endogenous human mechanism to deliver therapeutic payloads directly to the intended cells, avoiding the challenges associated with viral delivery approaches. This targeted approach aims to improve treatment efficacy and reduce the adverse effects commonly associated with traditional cancer therapies. The Zip-Codes™ are universally applicable and specific for each cell type.
Target Audience
The primary target audience includes oncologists and medical researchers seeking more effective and targeted cancer therapies, as well as patients with cancer who may benefit from treatments with fewer side effects.
Features
- Cell-specific targeting using the Zip-Code™ Technology platform
- Gene therapy delivery system based on an endogenous human mechanism
- Modular design adaptable for a range of cell and gene therapy applications
- Potential to reduce off-target effects and improve treatment tolerability